Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
123.05
-0.97 (-0.78%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
May 04, 2024
The anti-obesity medication stock is way up, and there could be more fuel in the tank.
Via
The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
May 03, 2024
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
Via
The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
May 03, 2024
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries.
Via
InvestorPlace
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Analyzing NYSE:NVO's Dividend Potential.
April 30, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals.
Via
Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
April 29, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
April 26, 2024
Via
Benzinga
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
May 03, 2024
To gain an edge, this is what you need to know today.
Via
Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
May 03, 2024
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug.
Via
InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
May 03, 2024
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses.
Via
InvestorPlace
This Is a Huge Sigh of Relief for Novo Nordisk Investors
May 03, 2024
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.
Via
The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
May 02, 2024
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand.
Via
Benzinga
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
April 25, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
Via
Chartmill
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
May 02, 2024
NVO earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target
May 02, 2024
Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance.
Via
Investor's Business Daily
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
May 02, 2024
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.
Via
Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
May 01, 2024
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips.
Via
InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
May 01, 2024
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and...
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
May 01, 2024
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid.
Via
InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
May 01, 2024
The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first.
Via
Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
May 01, 2024
We also look at the "treasure hunt" economy.
Via
The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
April 30, 2024
The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18.
Via
InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
April 30, 2024
Overall revenue fell short in Q1. Lilly stock is set to cross a key level.
Via
Investor's Business Daily
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
April 29, 2024
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
April 28, 2024
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Via
The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
April 27, 2024
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Via
The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
April 27, 2024
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Via
The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
April 27, 2024
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.